ReviewCurrent cardiology reports2025
Digital Therapeutics in Cardiovascular Healthcare: A Narrative Review.
Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Explainable Lightweight AI for the Identification of Right-Sided Cardiac Dysfunction in a Saudi Arabian Diabetic Cohort.Journal of clinical medicine · 2026Article
- Redox-Driven Precision Medicine for Life-Course Prevention of Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewThe rapid development of digital therapeutics (DTx) presents opportunities for cardiovascular diseases (CVD) intervention. This review aims to summarize the technologies and applications of DTx in the field of cardiovascular healthcare. It seeks to identify how DTx can enhance the effectiveness and efficiency of cardiovascular healthcare RECENT
findingsGiven the absence of a universally accepted definition, this review categorizes DTx applications in CVD into three main areas with based on widely recognized DTx characteristics: extended reality (XR)-assisted therapeutics, digital pill systems (DPS), and evidence-based applications designed for smartphones or smartwatches. XR aids surgical planning and execution by creating anatomical digital twins and providing immersive environments to reduce patient anxiety. DPS leverages ingestible sensors to enhance medication adherence and monitor physiological data, while APPs focus on CVD prevention, cardiac rehabilitation, and symptom tracking. Integrating artificial intelligence into DTx enhances its potential, allowing personalized interventions and improved data analysis. Despite its promise, the field faces challenges such as high costs, technological accessibility, and the need for robust regulatory frameworks to ensure safety and efficacy. With continued technological innovation and improved access, DTx is expected to play a transformative role in cardiovascular healthcare, bridging gaps in prevention, treatment, and long-term management CHARACTERISTICS: extended reality (XR)-assisted therapeutics, digital pill systems (DPS), and evidence-based applications designed for smartphones or smartwatches. XR aids surgical planning and execution by creating anatomical digital twins and providing immersive environments to reduce patient anxiety. DPS leverages ingestible sensors to enhance medication adherence and monitor physiological data, while APPs focus on CVD prevention, cardiac rehabilitation, and symptom tracking. Integrating artificial intelligence into DTx enhances its potential, allowing personalized interventions and improved data analysis. Despite its promise, the field faces challenges such as high costs, technological accessibility, and the need for robust regulatory frameworks to ensure safety and efficacy. With continued technological innovation and improved access, DTx is expected to play a transformative role in cardiovascular healthcare, bridging gaps in prevention, treatment, and long-term management. DTx show promise in the prevention, intervention, and management of CVD. Despite existing challenges, technological advancements and regulatory improvements are expected to expand the role of DTx in cardiovascular healthcare.
Indexed as
Identifiers
40742604What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.